Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
04/2003
04/17/2003WO2003031432A1 Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
04/17/2003WO2003031422A1 Novel benzothiazine derivatives, their preparation and use
04/17/2003WO2003031416A2 [[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
04/17/2003WO2003031414A1 Novel heterocyclic compound and anti-inflammatory agent
04/17/2003WO2003031412A1 Piperidine compounds as muscarinic antagonists
04/17/2003WO2003031410A1 Ligands of melanocortin receptors and compositions and methods related thereto
04/17/2003WO2003031407A2 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
04/17/2003WO2003031405A2 Methods for the synthesis of substituted purines
04/17/2003WO2003031398A1 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
04/17/2003WO2003030993A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
04/17/2003WO2003030944A2 Inhibition of stat-1
04/17/2003WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003WO2003030931A2 Vaccine against arthropod-borne infectious diseases
04/17/2003WO2003030930A1 Human 3 relaxin
04/17/2003WO2003030927A2 Use of thymulin-like peptides for making pain-relieving medicines
04/17/2003WO2003030920A1 An antispasmodic agent spaced drug delivery system
04/17/2003WO2003030914A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs)
04/17/2003WO2003030912A1 Prostaglandin analogs as chloride channel opener
04/17/2003WO2003030905A1 Dihydroorotate dehydrogenase inhibitor
04/17/2003WO2003030904A1 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
04/17/2003WO2003030902A1 Imidazole derivates as anti-inflammatory agents
04/17/2003WO2003030901A1 Arylsulphonyl-substituted tetrahydro- and hexahydro-carbazoles as 5-ht-6 receptor ligands
04/17/2003WO2003030900A1 Remedies for attention-deficient/hyperreactivity disorder
04/17/2003WO2003030899A2 Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
04/17/2003WO2003030897A1 Pyrrolidinone derivatives
04/17/2003WO2003030889A1 Para-amino benzoic acids as integrin antagonists
04/17/2003WO2003030886A2 Allylamides useful in the treatment of alzheimer's disease
04/17/2003WO2003030883A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
04/17/2003WO2003030878A2 Galenic microparticulate oral formulation
04/17/2003WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003WO2003030875A1 Over-coated chewing gum formulations including tableted center
04/17/2003WO2003030827A2 Compositions for and methods of treating and preventing sirs/sepsis
04/17/2003WO2003030823A2 Combinations for the treatment of immunoinflammatory disorders
04/17/2003WO2003017927A3 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
04/17/2003WO2003011293A3 Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
04/17/2003WO2003008457A3 Polysaccharidic esters of retinoic acid
04/17/2003WO2003007922A3 Pharmaceutical formulation containing an ltb4 antagonist
04/17/2003WO2003007887A3 Substituted imidazoles as cannabinoid receptor modulators
04/17/2003WO2003007875A3 Compounds with analgesic, antipyretic and/or anti-inflammatory activity
04/17/2003WO2003005999A3 Methods of treating cytokine mediated diseases
04/17/2003WO2002085943A3 Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof
04/17/2003WO2002085930A3 Immunomodulating agents from parasitic worms and method for isolation thereof
04/17/2003WO2002079221A3 Sapogenin derivatives, their synthesis and use
04/17/2003WO2002070706A3 Interleukin-8 homologous polypeptides and therapeutic uses thereof
04/17/2003WO2002050289A9 Methods for the production of multimeric proteins, and related compositions
04/17/2003WO2002050284A3 Oxidoreductases
04/17/2003WO2002032865A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
04/17/2003WO2002029036A3 Lipid metabolism enzymes
04/17/2003WO2002024891A3 B7-like molecules and uses thereof
04/17/2003WO2002018575A3 Genes expressed in the cell cycle
04/17/2003WO2002018445A3 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
04/17/2003WO2001078709A3 Treatment of neurodegenerative disease
04/17/2003WO2001072752A3 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS
04/17/2003WO1999064401A3 Imidazolyl derivatives and their use as somatostatin receptor ligands
04/17/2003US20030074223 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits
04/17/2003US20030073850 Incontinence; nasal congestion
04/17/2003US20030073849 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
04/17/2003US20030073846 Aminoalcohol derivatives
04/17/2003US20030073845 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
04/17/2003US20030073838 3-alkyl-3-phenyl-piperidines
04/17/2003US20030073744 Circadian rhythm disorders; sleep disorders
04/17/2003US20030073733 Pharmaceutically active compounds and methods of use
04/17/2003US20030073732 Antiinflammatory agents
04/17/2003US20030073729 Medicaments for diabetic complication and neuropathy, and uses thereof
04/17/2003US20030073727 Central nervous system disorders
04/17/2003US20030073726 Heterocyclic inhibitors of glycine transporter 2
04/17/2003US20030073725 Naphtalene derivatives and their pharmaceutical use
04/17/2003US20030073724 Central nervous system disorders
04/17/2003US20030073723 Antiinflammatory agents; rheumatic diseases; antiallergens
04/17/2003US20030073720 Tryptase inhibitors
04/17/2003US20030073719 Chiral salt resolution
04/17/2003US20030073718 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease
04/17/2003US20030073717 Therapy for nervous system disorders; anxiolytic agents; anticonvulsants
04/17/2003US20030073714 Prevent drug abruse; side effect reduction; administering mixture of opioid antagonist, releasable form and sequestering agent
04/17/2003US20030073712 Antiinflamamtory agents; antiischemic agents
04/17/2003US20030073707 Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
04/17/2003US20030073704 Analgesics; antidiabetic agents; antiinflamamtory agents
04/17/2003US20030073700 Central nervous system disorders; Parkinson's disease, Huntington's disease; psycological disorders
04/17/2003US20030073699 Compounds and methods to treat cardiac failure and other disorders
04/17/2003US20030073697 Schizophrenia, bipolar disorders, Parkinson's disease; drug abruse
04/17/2003US20030073693 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
04/17/2003US20030073692 Anticancer agents; viricides; Alzheimer's diseases
04/17/2003US20030073685 Nitric oxide synthase inhibitor; antiinflammatory agents
04/17/2003US20030073682 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
04/17/2003US20030073669 N-heterocyclic derivatives as NOS inhibitors
04/17/2003US20030073655 Alzheimer's disease
04/17/2003US20030073620 Genetic engineering; antibody binding to nucleic acid; disease therapy
04/17/2003US20030073610 Prevention protein misfolding; central nervous system disorders; Alzheimer's, Parkinson's, Huntington's disease therapy
04/17/2003US20030073609 Enhanced pharmacokinetic profile of intradermally delivered substances
04/17/2003US20030073218 Enzyme inhibitor for us in the treatment and prevention of tumors
04/17/2003US20030073167 DNA encoding SNORF36 receptors
04/17/2003US20030073132 Detecting modulators of brain membrane protein; obtain membrane protein, incubate with ligand and labeled compound, measure level of binding
04/17/2003US20030073123 Detection of modulators of gene transcription inhibition; obtain sample of cells, incubate with modulator, monitor transcription pattern, compare to control, evaluate for transcription inhibition
04/17/2003US20030072824 Having anti-oxidant, gastric mucosa injury inhibiting, aldose reductase inhibiting, blood glucose level elevation inhibiting action, platelet agglutination accelerating action, alcohol absorption inhibition, anti-inflammation properties
04/17/2003US20030072822 Methods for treating disorders using plant extracts
04/17/2003US20030072763 Absorb in the low- energy, ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum that are used for the phototherapy of tumors and other lesions
04/17/2003US20030072749 Applying at least one chondroitin sulfate proteoglycan-degrading enzyme to the damaged nerve for promoting repair of a damaged nerve
04/17/2003US20030072737 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
04/17/2003US20030072736 Human tumor necrosis factor receptor TR16
04/17/2003CA2473970A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
1 ... 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 ... 1833